Phosphorus
The skeletal and energy mineral where the real-world risk is excess, not deficiency
What is Phosphorus?
Phosphorus is a mineral used for corrects clinically significant hypophosphatemia (refeeding syndrome, severe alcoholism, recovery from dka, certain hereditary phosphate-wasting disorders) where supplementation is genuinely therapeutic. NutriDex grades the human evidence as Strong. Phosphorus (as phosphate) is an essential structural and metabolic mineral: roughly 85% resides in bone and teeth as hydroxyapatite, and the remainder is central to ATP energy transfer, nucleic acids (DNA/RNA), cell membranes (phospholipids), and acid-base buffering. Dietary deficiency is rare in people eating any normal diet because phosphorus is ubiquitous in food; clinically important hypophosphatemia instead arises from refeeding syndrome, alcoholism, hyperparathyroidism, or certain medications, and is treated with supplementation. There are essentially no supplementation trials showing benefit in already-replete people; on the contrary, observational and mechanistic data link high phosphorus intake—especially from highly bioavailable inorganic phosphate additives—to increased all-cause and cardiovascular mortality (NHANES III HR 2.23 above ~1400 mg/d) and to vascular calcification and elevated FGF23. The practical public-health message is to limit excess phosphate additives, not to supplement.
Purported Benefits
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Correction of clinical hypophosphatemia (refeeding, alcoholism, DKA)Genuinely therapeutic for documented hypophosphatemia; a 2026 meta-analysis confirms low phosphate predicts refeeding syndrome, supporting repletion. | Moderate | ↑ benefit · large | 2 |
| X-linked hypophosphatemia / renal phosphate-wastingOral phosphate is therapeutic but a phase-3 RCT and guideline now favor burosumab (anti-FGF23) over oral phosphate as first-line. | Moderate | ↔ mixed · moderate | 2 |
| Supplementation in non-deficient peopleNo trials show benefit in replete individuals; phosphorus is ubiquitous in diet so routine supplements are unnecessary. | Moderate | — no effect · negligible | 1 |
| All-cause / cardiovascular mortality from high intakeObservational: NHANES III linked intake >1400 mg/d to 2.23x all-cause mortality; a 7-cohort meta-analysis found 44% higher CV mortality with high serum phosphate. Not causal. | Moderate | ⚠ risk · moderate | 3 |
| Phosphate binders in CKD (mortality)A meta-analysis of 11 RCTs favored non-calcium binders over calcium (RR 0.78), but a 77-trial network meta-analysis found no mortality benefit vs placebo. | Mixed | ↔ mixed · moderate | 2 |